A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT06952010. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Dose Escalation and Expansion Study of XB628 as a Single Agent and in Combination With Zanzalintinib in Participants With Advanced or Metastatic Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE\[s\]); and the dose expansion stage is to evaluate the preliminary antitumor activity of XB628 as a single agent and in combination with zanzalintinib.
Study identification
- NCT ID
- NCT06952010
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 303 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2025
- Primary completion
- May 30, 2027
- Completion
- Nov 29, 2027
- Last update posted
- Jun 23, 2026
2025 – 2027
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Exelixis Clinical Site #5 | San Francisco | California | 94158 | Recruiting |
| Exelixis Clinical Site #4 | New Haven | Connecticut | 06520 | Recruiting |
| Exelixis Clinical Site #8 | Tampa | Florida | 33612 | Recruiting |
| Exelixis Clinical Site #10 | Boston | Massachusetts | 02114 | Recruiting |
| Exelixis Clinical Site #11 | Boston | Massachusetts | 02114 | Recruiting |
| Exelixis Clinical Site #6 | St Louis | Missouri | 63108 | Recruiting |
| Exelixis Clinical Site #7 | New York | New York | 10029 | Recruiting |
| Exelixis Clinical Site #1 | Hickory | North Carolina | 28602 | Recruiting |
| Exelixis Clinical Site #3 | Nashville | Tennessee | 37203 | Recruiting |
| Exelixis Clinical Site #9 | Houston | Texas | 77030 | Recruiting |
| Exelixis Clinical Site #2 | San Antonio | Texas | 78229 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06952010, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 23, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06952010 live on ClinicalTrials.gov.